Valthos, Inc.

Based in the US, Valthos develops artificial intelligence-driven solutions for biodefense, focusing on enhancing public health security through innovative technologies. Valthos, Inc. is a biodefense firm founded in 2024 and headquartered in New York, US. The company specializes in developing systems to address biodefense challenges but has not reported any significant pivots in its business strategy.

Valthos, Inc. is a biodefense firm founded in 2024 and headquartered in New York, US. The company specializes in developing systems to address biodefense challenges but has not reported any significant pivots in its business strategy. In August 2025, Valthos raised USD 27.

50 million in seed funding co-led by new investors OpenAI Startup Fund, Lux Capital, and Founders Fund, with participation from another new investor Definition Capital. Other unspecified investors also participated in the round. Valthos specializes in advanced biodefense solutions, focusing on the development and deployment of innovative products aimed at enhancing public health security. Their core offerings address various biodefense challenges, including pathogen detection, vaccine development, and rapid response systems for biological threats.

These solutions are particularly relevant to government and military sectors, serving end users like public health agencies and emergency response teams across North America, Europe, and parts of Asia. Valthos generates revenue through a structured model emphasizing B2B transactions with government agencies and defense organizations. The company engages in contracts often involving multi-year agreements for its biodefense products and services, along with partnerships for co-development of tailored technologies. Clients typically participate in both direct purchases and long-term subscription agreements, ensuring a continuous revenue stream as they rely on Valthos for essential biodefense capabilities.

In August 2025, Valthos raised USD 30. 00 mn in Seed funding to exit stealth mode and develop AI-powered tools designed to detect and counter bioweapon threats. The company plans to expand its offerings into new markets, with targeted growth initiatives for the next few years that aim to enhance its presence in the biodefense sector. The recent funding will support these efforts as Valthos accelerates the development of new products and seeks to establish a stronger foothold in the global market.